Mega-cap AI listings have become a summer tradition. SpaceX (NASDAQ:SPCX | SPCX Price Prediction) went public in June at a $1.77 trillion valuation, instantly becoming one of the largest debuts in stock market history. Now Anthropic wants the crown outright.
Six of the Claude maker’s investors told the Financial Times this week that they expect an October IPO priced at $2 trillion or more — a number that would eclipse SpaceX and make Anthropic the largest initial public offering ever completed.
That’s not company guidance. Anthropic’s own executives haven’t set a valuation target, even privately, the FT reported. This is backers doing math on a spreadsheet, and the math is aggressive enough that I’m more than comfortable with staying on the sidelines when shares eventually list.
The Numbers Behind the $2 Trillion Number
Let’s start with what Anthropic actually reveals, because that’s where the story becomes less magical. The company reported $47 billion in annualized revenue as of May, according to the Financial Times. Backers now expect that figure to reach $100 billion to $120 billion by year-end — more than a tenfold jump in a single calendar year. At $2 trillion against $47 billion in stated revenue, Anthropic would trade at roughly 43 times sales.
One investor went further, telling the FT that 800% annual growth justifies at least 30 times revenue at the low end — arithmetic that implies a $3 trillion valuation once the full-year run rate lands. Here’s how that stacks against public comparables:
| Company | Reported Multiple |
| Anthropic (at $2 trillion target) | ~43x annualized revenue |
| Palantir Technologies (NYSE:PLTR) | ~70x sales |
| Nebius Group (NASDAQ:NBIS) | ~52x sales |
Surprisingly, 43 times isn’t the outlier here — it’s actually below where Palantir and Nebius already trade. That’s the bull case in one sentence: on a pure multiple basis, Anthropic’s ask looks conservative next to what public markets already pay for AI exposure.
What the Multiple Doesn’t Price In
That said, a favorable multiple only matters if the growth holds, and Anthropic’s June was a preview of what can go wrong. The Commerce Department’s export controls forced Anthropic to briefly pull Fable 5 and Mythos 5 — its two most advanced models — and two investors told the FT that the ban measurably slowed revenue growth that month before access was restored.
Anthropic is also in active litigation with the War Dept., which labeled the company a supply-chain risk. And pricing pressure is real: Anthropic’s top model costs more than 2.5 times what OpenAI’s flagship charges, while Chinese open-weight alternatives are available for a fraction of that. None of that shows up in a revenue-multiple table, but all of it can compress one.
The First-Day Trap
In any case, the multiple math is only half the risk — the other half is what happens the moment trading opens. Meta Platforms (NASDAQ:META) priced its 2012 IPO as Facebook at $38 a share, a $104 billion valuation at the time. By September, shares traded below $18, and the stock needed 15 months just to reclaim its offer price — even as the underlying business kept growing the whole time. SpaceX and SK Hynix (NASDAQ:SKHY) both slid hard after their own recent listings once public investors began applying real-time scrutiny to private-market prices. Growth didn’t collapse in any of those cases. Sentiment did.
According to Nasdaq research, nearly 64% of IPOs underperform the broader market over their first three years. Many trail by more than 10 percentage points as the initial hype fades and valuations normalize. Moreover, the bigger the IPO, the worse the odds for investors over the following year.
Key Takeaway
Anthropic’s revenue trajectory is genuinely rare — a projected tenfold jump to $100 billion-plus in a single year is not something most companies ever achieve. Granted, the multiple math even supports a case for $3 trillion. But day-one pricing on a $2 trillion IPO leaves almost no room for error.
In short, I’d rather watch Anthropic’s first two or three quarters as a public company to let it acclimate to the market before deciding whether the stock — not the story — deserves my money.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks